|
|
 Previous Article | Table of Contents | Next Article 
Identification and characterization of a new surface membrane antigen found
predominantly on malignant B lymphocytes
RD Gingrich, CE Dahle, KF Hoskins and MJ Senneff
University of Iowa College of Medicine, Iowa City.
A monoclonal antibody, 1D10, was derived that identifies a new antigenic
epitope on the surface of malignant B lymphocytes. Normal resting and
stimulated lymphocytes do not express the antigen. The majority of
individuals with acute Epstein-Barr virus infection express the antigen on
their lymphocytes, and in these patients, the T lymphocyte may also be
antigen positive. The antigen was found on B- lymphoid neoplasia from the
early pre-B cell stage through terminally differentiated plasma cells, a
characteristic not reported for other B cell-associated antigens. Studies
on homozygous typing cells and cells from individuals with known HLA
phenotypes indicate that the antigen does not segregate in a pattern
characteristic for major histocompatibility antigens. The molecule is a
heterodimeric polypeptide with the molecular weight and isoelectric points
of the alpha and beta chains being 32,000 d/4 and 28,000 d/6, respectively.
Evidence is presented that the 1D10 molecule is not HLA-DR, -DP, or - DQ.
By extrapolation, we suggest that this novel molecule may represent HLA
D-region gene expression of a gene(s) not normally expressed. Potential
candidates are D-region pseudogenes. We conclude that the antigenic epitope
identified by the 1D10 monoclonal antibody is unique among previously
described B-lymphocyte antigens. Further studies of the factors controlling
the expression of this molecule, as well as studies designed to look at the
possible cellular function, may provide insights for understanding crucial
events in the malignant transformation of lymphocytes.
Volume 75,
Issue 12,
pp. 2375-2387,
06/15/1990
Copyright © 1990 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
C. Carlo-Stella, M. Di Nicola, M. C. Turco, L. Cleris, C. Lavazza, P. Longoni, M. Milanesi, M. Magni, M. Ammirante, A. Leone, et al.
The Anti-Human Leukocyte Antigen-DR Monoclonal Antibody 1D09C3 Activates the Mitochondrial Cell Death Pathway and Exerts a Potent Antitumor Activity in Lymphoma-Bearing Nonobese Diabetic/Severe Combined Immunodeficient Mice
Cancer Res.,
February 1, 2006;
66(3):
1799 - 1808.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. P. Mone, P. Huang, H. Pelicano, C. M. Cheney, J. M. Green, J. Y. Tso, A. J. Johnson, S. Jefferson, T. S. Lin, and J. C. Byrd
Hu1D10 induces apoptosis concurrent with activation of the AKT survival pathway in human chronic lymphocytic leukemia cells
Blood,
March 1, 2004;
103(5):
1846 - 1854.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. E. Juweid
Radioimmunotherapy of B-Cell Non-Hodgkin's Lymphoma: From Clinical Trials to Clinical Practice
J. Nucl. Med.,
November 1, 2002;
43(11):
1507 - 1529.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. W. Press, J. P. Leonard, B. Coiffier, R. Levy, and J. Timmerman
Immunotherapy of Non-Hodgkin's Lymphomas
Hematology,
January 1, 2001;
2001(1):
221 - 240.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
